M2.2 protein-deficient low-toxicity avian metapneumovirus vaccine strain as well as construction method and application thereof
The low-virulent avian metapneumovirus vaccine strain with missing M2.2 protein was constructed through reverse genetics system, which solved the problem of long preparation cycle and risk of return to strength by avian metapneumovirus attenuated vaccine, and achieved low virulence characteristics and preparation cycle The shortening of the avian metapneumovirus vaccine provides a safe and efficient solution.
Patent Information
- Application Number
- CN202410849428.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-27
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the attenuated vaccine of avian metapneumonia has a long preparation cycle and a risk of returning to strength, making it difficult to meet the demand for low-virulence strains.
The low-virulent avian metapneumovirus vaccine strain with missing M2.2 protein was constructed through reverse genetics system. Multi-fragment sequencing splicing and mutant plasmid construction methods were used to silence the expression of M2.2 protein to obtain subtype B avian metapneumovirus Infectious clones and rescue strains in Vero cells ensure the low virulence properties of the strain and the shortening of preparation cycles.
The low virulence characteristics and shortening of the preparation cycle of the avian metapneumovirus vaccine have been achieved without the risk of returning to strength, and it provides a safe and efficient vaccine candidate strain suitable for the application of chicken respiratory infectious disease vaccines.
Smart Images

Figure CN118931853A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a low-virulence avian metapneumovirus vaccine strain lacking an M2.2 protein, and a construction method and application thereof. Background Art
[0002] Avian Metapneumovrus (aMPV) is a non-segmented negative-strand RNA enveloped virus that can infect a variety of poultry species, with chickens and turkeys being its main susceptible hosts. aMPV causes swollen head syndrome in chickens, resulting in a significant decline in production performance such as egg production and weight gain, causing huge economic losses to the poultry industry. Based on the homology of viral proteins, aMPV can be divided into four subtypes, ABCD, of which subtypes A and B are prevalent in Africa and Europe, and type C is the main prevalent strain in the Americas. my country completed the first identification of aMPV in 1999, and there have been reports of strain isolation in recent years. Subtype B and subtype C strains are currently the main strains in my country.
[0003] Reverse genetics technology can modify viruses at the viral gene level and explore the effects of these changes on viral structure and function, host interaction, and infection immunity. It is an important tool for virus research. At present, there have been reports on reverse genetics systems for epidemic strains of aMPV of subtypes A and C in Europe and America. The lack of reverse genetics operating systems corresponding to epidemic strains in China directly limits the research on aMPV. Metapneumovirus needs to be used in combination with attenuated vaccines and inactivated vaccines. Inactivated vaccines are easy to prepare, while attenuated vaccines require a long period of time by attenuating through passage, and there is a possibility of re-strengthening. Whether it is the preparation of inactivated vaccines or attenuated vaccines, avian metapneumovirus requires reliable low-virulence strains. The most commonly used method is to attenuate through passage in cells. Although this method is effective, the overall cycle is too long. According to the method of passage every 4 to 5 days, it takes about one to one and a half years to obtain a strain that has been passaged 50 times.
[0004] Therefore, the prior art needs to be further developed. Summary of the invention
[0005] The purpose of the present invention is to overcome the above-mentioned technical deficiencies and provide a low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein and its construction method and application, so as to solve the technical problems of the existing attenuated vaccines in the related technology that have the risk of reversion to strong viruses and the long preparation cycle.
[0006] In order to achieve the above technical objectives, the present invention adopts the following technical scheme: providing a low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein, obtained by a reverse genetics system, wherein the vaccine strain is aMPV B subtype and lacks the M2.2 protein.
[0007] Furthermore, the vaccine strain is deposited in the China Center for Type Culture Collection with the deposit number CCTCCNO: V202460.
[0008] A method for constructing a low-virulence avian metapneumovirus vaccine strain lacking M2.2 protein comprises the following steps: (1) construction of a whole genome cDNA plasmid: obtaining the whole genome sequence of aMPV B subtype virus by a multi-fragment sequencing and splicing method, and obtaining a whole genome cDNA plasmid based on the whole genome sequence; (2) construction of a mutant plasmid: synthesizing the sequence fragment required for the M2.2 mutation to prevent M2.2 from being expressed, using primers to amplify the M2.2 fragment containing the mutation, and introducing the mutation fragment into the whole genome cDNA plasmid through seamless connection to obtain a pBR-aMPV-muM2.2 genome plasmid containing the mutation site; (3) construction of an auxiliary plasmid: using the whole genome cDNA plasmid as a template to amplify the ORF fragments of N, P, M2.1, and L, respectively, and introducing them into a linearized vector to obtain a pC I-N, pCI-P, pCI-M2.1 and pCI-L expression plasmids; using pCI-N as a template, amplify the N gene expression cassette sequence, using pCI-P as a template, amplify the P gene expression cassette sequence, introduce the two expression cassette sequences into the pCI-M2.1 plasmid, and obtain the pCI-NPM2.1 expression plasmid; (4) Virus rescue: transfect the pBR-aMPV-muM2.2, pCI-NPM2.1 and pCI-L plasmids into host cells and co-culture them with Vero cells. After the virus is collected, it is continuously blindly propagated in Vero cells until lesions appear, and the virus is collected to obtain the rescued strain.
[0009] Furthermore, the terminal sequences of the 3' and 5' ends of the viral genome were obtained using the RACE method, and the remaining viral genome fragments were obtained by RT-PCR amplification in five segments, and all amplified fragments were spliced to obtain the whole genome sequence;
[0010] Furthermore, the promoter of M2.2 was silenced in the sequence fragment and multiple terminators were added after the subsequent M2.1 ORF, so as to completely abolish the expression of M2.2 protein without affecting M2.1, thereby obtaining the non-expressed M2.2 gene sequence, as shown in SEQ ID NO:24.
[0011] Furthermore, the auxiliary plasmid vector was digested with EcoRI and SalI restriction endonucleases to obtain a linearized vector.
[0012] Furthermore, pCI-M2.1 was digested with BamHI to obtain a linearized plasmid.
[0013] Furthermore, transfection was performed according to the molar ratio of plasmids pBR-aMPV-M2.2:pCI-NPM2.1:pCI-L of 4:2:1.
[0014] Application of low-virulence avian metapneumovirus vaccine strain lacking M2.2 protein in the preparation of chicken respiratory infectious disease vaccines.
[0015] Beneficial effects:
[0016] The present invention obtains an isolated infectious clone of subtype B metapneumovirus and prepares a strain lacking M2.2 protein for the first time through reverse genetics system operation. The lacking strain has the characteristics of low virulence, short preparation cycle and no risk of reversion, and can be used as a candidate strain for vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 is the result of amplification of the whole genome sequence of aMPV B subtype virus of the present invention; wherein, Figure 1 In A, 1 is the 3' RACE amplification band, 2 is the 5' RACE amplification band, and M is the DL5000 Marker; Figure 1 In B, 1 to 5 are amplified bands F2 to F6 in Table 1, and M is DL5000 Marker.
[0018] Figure 2 This is the genetic evolution tree of the aMPV B subtype N gene of the present invention.
[0019] Figure 3 It is a schematic diagram of the M2.2 mutation of the present invention.
[0020] Figure 4 It is a schematic diagram of the construction of the pBR-aMPV-muM2.2 plasmid of the present invention; wherein, HdvRz&T7ter are hepatitis D ribozyme and T7 RNA polymerase transcription terminator, and Mlu I, Xho I, Kpn I, Not I are specific restriction endonuclease sites contained in the plasmid.
[0021] Figure 5 This is the identification result of the cDNA plasmid of the present invention; wherein, 1 is the XhoI-NotI restriction fragment, 2 is the MluI-KpnI restriction fragment, 3 is the MluI-NotI restriction fragment, and M is the DL15000 Marker.
[0022] Figure 6 It is the result of restriction enzyme digestion identification of the cDNA plasmid of the M2.2 mutant plasmid of the present invention; wherein, 1 to 3 are XhoI-BamHI restriction enzyme digestion fragments, and M is DL15000 Marker.
[0023] Figure 7 It is a schematic diagram of the construction of the auxiliary plasmid and minigenome plasmid of the present invention; wherein A is the pCI-NPM2.1 auxiliary plasmid, and B is the pCI-L auxiliary plasmid.
[0024] Figure 8is the result of enzyme digestion identification of the auxiliary plasmid and minigenome plasmid of the present invention; wherein, Figure 8 A is pCI-NPM2.1 plasmid, 1 is PspOM I-EcoR V-Kpn I, and M is DL15 kb Marker; Figure 8 B is pCI-L plasmid, 1 is Kpn I, and M is DL15kb Marker.
[0025] Fig. 9 The left picture is a picture of cell lesions under a microscope of the present invention; wherein, the left picture is a picture of Vero cells incubated with aMPV / B-CF strain F5 generation for 120 hours, and the right picture is a Vero cell control.
[0026] Fig.10 It is the M2.2 gene detection result of the present invention; wherein, M is a 2000 bp marker, 1-2 is the 5th passage, 3-4 is the 10th passage, and 5-6 is the 15th passage.
[0027] Fig.11 It is the clinical disease index curve after the virus attack of the present invention.
[0028] Fig.12 It is the detection of viral load of nasopharyngeal swab after virus attack according to the present invention. DETAILED DESCRIPTION
[0029] In order to enable those skilled in the art to better understand the solution of the present application, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present application.
[0030] aMPV is a non-segmented negative-strand RNA envelope virus. The total length of the B subtype aMPV genome is about 13.5kb. From the 3' end of the genome, NPMF-M2-SH-GL are arranged in sequence, with a total of 8 genes, among which M2 can encode two proteins, M2.1 and M2.2, through frameshift transcription. The viral envelope contains four structural proteins, M, F, SH and G. N, P, M2 and L encapsulate the viral negative-strand RNA genome to form a ribonucleoprotein complex (RNP). The exposed viral RNA is not infectious. RNP is the basic unit for viral gene transcription and replication. The lack of reverse genetics operating system corresponding to the epidemic strain in China directly limits the research of aMPV. This embodiment obtains the infectious clone of the isolated B subtype metapneumovirus and prepares the M2-2 protein deletion strain for the first time through reverse genetics system operation. The deletion strain has the characteristics of low virulence, and the preparation cycle is short, there is no risk of reversion, and it can be used as a candidate strain for the vaccine. The method for constructing a low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein in this embodiment solves the technical problems of the risk of reversion to strong virus and the long preparation cycle of the existing attenuated vaccines in the related art.
[0031] Example 1: Whole genome sequencing of subtype B strain
[0032] The aMPV subtype B strain was isolated in 2022 from nasal swabs of 80-day-old sick laying hens in a chicken farm in Chifeng City, Inner Mongolia.
[0033] Snapgene7 software was used to align the whole genome sequences of aMPV B subtype strain LN16 (GenBank ID: MH745147), Hungary / 657 / 4 (GenBank ID: MN729604) and VCO3 / 60616 (GenBank ID: AB548428). The RACE method was used to obtain the terminal sequences of the 3' and 5' ends of the viral genome. Five segments of RT-PCR amplification were performed to obtain the remaining viral genome fragments. All amplified fragments were spliced to obtain the genome sequence. The primers are shown in Table 1. The primer sequences of 3'RACEprimer and 5'RACEprimer are shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The primer sequences of the five segments F2F / R, F3F / R, F4F / R, F5F / R and F6F / R are shown in SEQ ID NO: 3-12, respectively.
[0034] Table 1 Primers for whole genome sequencing of viruses
[0035]
[0036] The sequencing results were aligned with the aMPV N gene sequences of the four ABCD subtypes published on NCBI using Megalign11 software to obtain the viral nucleic acid development tree.
[0037] The results showed that the RACE method obtained the terminal fragments of about 1900 bp at the 3' end and about 1700 bp at the 5' end of the genome, such as Figure 1 As shown in A. The remaining genome sequence was obtained by five-segment amplification by RT-PCR method, as shown in Figure 1 As shown in B. The accurate genome sequence of aMPV / B strain was obtained by seven-segment sequencing and splicing. The full length of the genome of aMPV / B strain is 13516 nt, which is consistent with the genome structure of the subtype B reference strain and contains open reading frame sequences of 8 viral proteins.
[0038] The results of the viral nucleic acid development tree showed that the isolated strain was a subtype B avian metapneumovirus, belonging to the same branch as the representative subtype B strain VCO-60616. Under the subtype B branch, the isolated strain had a high affinity with WH2022 and LN16 identified in my country, such as Figure 2 This indicates that the strains in my country have a tendency to evolve independently, and it is necessary to prepare vaccine strains against the prevalent strains in my country.
[0039] Example 2 Construction of full genome cDNA plasmid
[0040] Design primers for plasmid construction based on the complete gene sequence, such as Figure 2 As shown, the viral cDNA was divided into four segments A-D, and segments A and D were amplified and introduced into the linearized low-copy plasmid by seamless ligation. The plasmid with segments A and D was linearized using restriction endonucleases Xho I and Kpn I, and segments B and C were amplified and introduced into the plasmid.
[0041] like Figure 3 As shown, the sequence fragment required for the M2.2 mutation was synthesized, its promoter was silenced and multiple terminators were added after the subsequent M2.1 ORF, so as to completely abolish the expression of M2.2 protein without affecting M2.1. The synthetic M2.2 gene sequence is shown in SEQ ID NO: 24.
[0042] SEQ ID NO: 24 (mutated codons are underlined)
[0043] ACG CCAATAGTAATACCCTGCAAAAGGGTGACAGCAGTAATTAAG TGA AACACC TGAGGTGTATAGCTGTTTAAGAGGACATATGAGCATAACATCATTAACCTTGGTGATCTGATAGAAGAAGTAGCAAGGTAAATTATTATAGATCACATAAATAGAAAACAATGCAATGAATGTAGAAAAGATTTTGAATTTGTAGCAGTTTACACATCTTACACTTAG
[0044] Mutation plasmid primers were designed according to the synthetic sequence and cDNA plasmid sequence, and the genomic plasmid amplification primers are shown in Table 2. Primers muM2.2F / R (primer sequences are shown in SEQ ID NO: 13 and SEQ ID NO: 14, respectively) were used to amplify the M2.2 fragment containing the mutation, and VecM2.2-1F / R and VecM2.2-2F / R (primer sequences are shown in SEQ ID NO: 15-18, respectively) were used to amplify the genomic plasmid backbone, and the three segments were seamlessly connected to introduce the mutation fragment into the genomic plasmid to obtain a genomic plasmid containing the mutation site, which was named pBR-aMPV-muM2.2.
[0045] Table 2 Primers for genomic plasmid amplification
[0046]
[0047] Note: The underlined sequences are homology arm sequences.
[0048] like Figure 4 As shown in the figure, the cDNA plasmid constructed by connecting four segments was double-digested with Xho I and Not I to obtain 11,646 bp and 5,279 bp of restriction fragments, double-digested with Kpn I and Mlu I to obtain 10,594 bp and 6,331 bp of restriction fragments, and double-digested with Mlu I and Not I to obtain 13,679 bp and 3,246 bp of restriction fragments. The plasmid restriction enzyme digestion was correct (as shown in the figure). Figure 5 and Figure 6 The pBR-aMPV-muM2.2 plasmid was digested with XhoI-BamHI to obtain a 4215 bp target fragment containing the mutation point and a 12710 bp backbone fragment. Further sequencing verification indicated that the constructed plasmid was correct.
[0049] Example 3 Auxiliary plasmid construction
[0050] like Figure 7As shown, the pCI-Neo plasmid vector was digested with EcoRI and SalI restriction endonucleases to obtain a linearized vector. The ORF fragments of N, P, M2.1, and L were amplified using the whole genome plasmid as a template, and introduced into the linearized vector to obtain pCI-N, pCI-P, pCI-M2.1, and pCI-L expression plasmids. The number of plasmids was further streamlined, and pCI-M2.1 was digested with BamHI to obtain a linearized plasmid. Using pCI-N as a template, the N gene expression cassette sequence was amplified. Using pCI-P as a template, the P gene expression cassette sequence was amplified, and the two expression cassette sequences were introduced into the pCI-M2.1 plasmid to obtain the pCI-NPM2.1 expression plasmid.
[0051] The identification results showed that the auxiliary plasmid pCI-NPM2.1 was digested with PspOM I, EcoR V and Kpn I to obtain enzyme fragments of 5824 bp, 2412 bp and 2073 bp ( Figure 8 A). After the auxiliary plasmid pCI-L was digested with Kpn I, 7731 bp and 3744 bp fragments were obtained ( Figure 8 B) Further sequencing showed that the gene sequences inserted into the two helper plasmids were correct.
[0052] Example 4 Virus rescue
[0053] BHK-T7 cells were plated in a 10 cm cell culture dish, and transfected according to the instructions of liposome transfection when the cell roundness exceeded 80%. The transfection was carried out according to the molar ratio of plasmid pBR-aMPV-M2.2: pCI-NPM2.1: pCI-L of about 4:2:1, and the transfected cells were co-cultured with Vero cells. After the virus was collected, the virus was continuously blindly propagated in Vero cells until the lesions appeared and the virus was collected to obtain the rescued strain. The obtained strain was continuously propagated to the 15th generation, and the primer M2.2 gene was used to detect F / R (as shown in Table 3, and the sequence is shown in SEQ ID NO: 19 and SEQ ID NO: 20, and the stability of the mutation was determined.
[0054] Table 3 Virus identification and detection primers
[0055]
[0056] The results showed that the rescued strains could produce the same cytopathic effects as the parent strains. The CPE changes over time were manifested as a slowdown in cell growth rate, vacuolar degeneration, the appearance of a large number of small-scale syncytia, and late cell disintegration and necrosis leading to a large number of shedding (such as Fig. 9 After 15 generations of continuous passage, the results of PCR and sequencing showed that the M2.2 gene had not undergone a back mutation and the mutation site could exist stably (as shown in Fig.10The rescued point mutation strain was named aMPV / B-CF strain, and was deposited in China Center for Type Culture Collection on June 6, 2024, with a deposit number of CCTCC NO: V202460, and a classification name: Subtype B avian metapneumovirus aMPV / B-CF strain Metapneumovirus, and the deposit address is Wuhan, China.
[0057] Example 5 Pathogenicity test of rescued strains
[0058] Forty-five 3-week-old SPF chickens were randomly assigned to three groups and kept in isolation under the same conditions. The F4 generation aMPV / B-CF strain and its parent strain were cultured at 4×10 4 The TCID50 challenge dose was inoculated into 3-week-old SPF chickens by nasal drops and eye drops, and the control group was inoculated with the same dose of PBS. The incidence was observed every day after the challenge. After the challenge, the disease was observed once in the morning and afternoon every day, and the corresponding footmarks were recorded to calculate the overall incidence. Normal was recorded as 0 points, shaking the head and scratching the nose for moist nasal cavity was recorded as 1 point, and runny nose was recorded as 2 points. The incidence index was recorded as the standard. After the challenge, the nasopharyngeal swabs of each group of chickens were collected every day, the viral RNA in the swabs was extracted, and the q-probe was used as the probe and qF / R was used as the primer as shown in SEQ ID NO: 21-23 (Table 3) to perform fluorescent quantitative RT-qPCR to determine the virus content and the detoxification cycle.
[0059] The results showed that the low-generation maternal strain aMPV / B strain was pathogenic to 3-week-old SPF chickens. During the onset period, the overall mental state of the chickens was depressed, and they were sleepy and liked to lie down. There were obvious respiratory symptoms, manifested as frequent head shaking and nose scratching, clear mucus in the nasal cavity, and yellow mucus and yellow scabs in the nasal cavity of a few chickens. The overall incidence of the maternal strain reached 100%. Compared with the maternal strain, the aMPV / B-CF strain was less pathogenic to 3-week-old SPF chickens and showed mild symptoms, without an obvious onset period. The overall mental state of the chickens was good after the infection. A few chickens showed head shaking and nose scratching after the infection, but no current symptoms were observed. The incidence of the chickens was reduced to 13.3%, as shown in Table 4.
[0060] Table 4 Statistics of disease incidence after virus attack
[0061]
[0062] like Fig.11 The morbidity index curve (n=15) shown in the figure shows that the overall pathogenicity level of the attenuated strain of aMPV / B-CF is lower than that of its parent strain. The degree of disease is significantly reduced, and the peak value of the morbidity index of the diseased chicken is about 0.133, which is significantly lower than the peak value of the morbidity index of 1.4 of its parent strain. The curve also shows that the symptom cycle of the attenuated strain of aMPV / B-CF chicken flock is about 4 to 5 days, which is lower than the 7 to 8 days of the parent strain.
[0063] like Fig.12 The detoxification curve shown (n=15) shows that the detoxification cycle of the mother strain aMPV / B is about 5 days. There is a two-day incubation period after the virus attack. The detoxification peaks on the third day, and then the detoxification level gradually decreases, and the detoxification stops on the seventh day. Compared with the detoxification cycle of the mother strain, the detoxification peak period of the aMPV / B-CF attenuated strain is shortened to two days. During the detoxification peak on the third and fourth days, the detoxification level of the aMPV / B-CF attenuated strain was significantly lower than that of its mother strain. The overall detoxification level of the aMPV / B-CF attenuated strain is significantly lower than that of its mother strain.
[0064] The above test results show that the aMPV / B-CF strain shows obvious attenuation characteristics compared with its parent strain, and this strain can be used as a candidate strain for vaccine strain.
[0065] Example 6 aMPV / B-CF strain reactivation test
[0066] Table 5 Grouping of strain reversion test
[0067]
[0068] As shown in Table 5, 12 1-week-old SPF chicks were randomly divided into 2 groups, 6 in each group. One experimental group and one control group. The chicks in the experimental group were challenged with 10 4 The attenuated strain of TCID50, the control group was immunized with an equal volume of PBS, and isolated in the isolator. Every 3 days, 6 1-week-old SPF healthy chicks were placed in each isolator. Finally, 5 batches of chicks were placed in each isolator, and each batch was marked with feet. After the last batch was placed, it was observed for another 2 weeks. During the experimental period, the condition of the chickens was observed every day and the disease phenomena were recorded.
[0069] The results showed that the mental state of the batches of test chickens released subsequently after the virus attack was normal, and no obvious respiratory symptoms occurred, which was no significant difference from the control group experiment, indicating that the M2.2 deletion strain did not have a relapse of virulence in the chicks.
[0070] The present invention prepares a virus reverse genetics system of the B subtype avian metapneumovirus epidemic strain in my country, and prepares the B subtype avian metapneumovirus M2.2 gene-deficient strain for the first time. The entire strain preparation cycle is about 1 month, which greatly shortens the preparation cycle, and the prepared gene-deficient strain shows lower pathogenicity. The present invention has a different method for knocking out the M2.2 gene. In addition to silencing the promoter, a stop codon is additionally added to ensure that the M2.2 protein is not expressed, while reducing the probability of gene back mutation. The currently common five-plasmid rescue system is improved by the present invention by changing the five-plasmid system to a three-plasmid system, which helps to improve the rescue efficiency.
[0071] It should be noted that the terms "first", "second", etc. in the specification and claims of the present application and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchangeable where appropriate, so that the embodiments of the present application described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any of their variations are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device comprising a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.
[0072] Optionally, the specific examples in this embodiment may refer to the examples described in the above embodiments, and this embodiment will not be described in detail here.
[0073] The serial numbers of the above-mentioned embodiments of the present application are for description only and do not represent the advantages or disadvantages of the embodiments.
[0074] In the above embodiments of the present application, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, please refer to the relevant description of other embodiments.
[0075] The above is only a preferred implementation of the present application. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present application. These improvements and modifications should also be regarded as the scope of protection of the present application.
Claims
1. A low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein, It is characterized in that The vaccine strain was obtained through a reverse genetics system. It is aMPV B subtype and lacks M2.2 protein.
2. The low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein according to claim 1, It is characterized in that The vaccine strain is deposited in China Center for Type Culture Collection with the deposit number CCTCCNO: V202460.
3. A method for constructing a low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein as described in claim 1 or 2, It is characterized in that The following steps are involved: (1) Construction of whole genome cDNA plasmid: The whole genome sequence of aMPV subtype B virus was obtained by multi-fragment sequencing and splicing, and the whole genome cDNA plasmid was obtained based on the whole genome sequence; (2) Construction of mutant plasmid: synthesize the sequence fragment required for the M2.2 mutation to prevent M2.2 from being expressed, use primers to amplify the M2.2 fragment containing the mutation, and introduce the mutation fragment into the whole genome cDNA plasmid through seamless ligation to obtain a genomic plasmid containing the mutation site. The genomic plasmid is named pBR-aMPV-muM2.2; (3) Construction of auxiliary plasmids: Using the whole genome cDNA plasmid as a template, the ORF fragments of N, P, M2.1, and L were respectively amplified and introduced into the linearized vector to obtain pCI-N, pCI-P, pCI-M2.1, and pCI-L expression plasmids; using pCI-N as a template, the N gene expression cassette sequence was amplified, and using pCI-P as a template, the P gene expression cassette sequence was amplified, and the two expression cassette sequences were introduced into the pCI-M2.1 plasmid to obtain the pCI-NPM2.1 expression plasmid; (4) Virus rescue: pBR-aMPV-muM2.2, pCI-NPM2.1, and pCI-L plasmids were transfected into host cells and co-cultured with Vero cells. After the virus was collected, the virus was continuously blindly propagated in Vero cells until pathological changes occurred, and the virus was collected to obtain the rescued strain.
4. The construction method according to claim 3, It is characterized in that The RACE method was used to obtain the terminal sequences of the 3' and 5' ends of the viral genome, and the remaining viral genome fragments were amplified in five segments using RT-PCR. All amplified fragments were spliced to obtain the full genome sequence.
5. The construction method according to claim 3, It is characterized in that The promoter of M2.2 was silenced in the sequence fragment and multiple terminators were added after the subsequent M2.1 ORF, so that the expression of M2.2 protein was completely abolished without affecting M2.1, and the non-expressed M2.2 gene sequence was obtained, as shown in SEQ ID NO:
24.
6. The construction method according to claim 3, It is characterized in that The helper plasmid vector was digested with EcoRI and SalI restriction endonucleases to obtain a linearized vector.
7. The construction method according to claim 6, It is characterized in that pCI-M2.1 was digested with BamHI to obtain a linearized plasmid.
8. The construction method according to claim 3, It is characterized in that Transfection was performed at a molar ratio of 4:2:1 of plasmids pBR-aMPV-M2.2:pCI-NPM2.1:pCI-L.
9. Use of the low-virulence avian metapneumovirus vaccine strain lacking the M2.2 protein as claimed in claim 1 or 2 in the preparation of vaccines for chicken respiratory infectious diseases.
